4 citations
,
April 2016 in “Journal of Dermatology Research and Therapy” Anti-androgens are safe and effective for treating moderate to severe adult female acne.
22 citations
,
March 2003 in “Steroids” PM-9 and finasteride effectively inhibit the enzyme that converts testosterone to DHT.
September 2025 in “Journal of Medical Case Reports” Finasteride is safe and effective for hair loss in transgender men, but may affect testosterone therapy.
14 citations
,
January 2003 in “Actas Urológicas Españolas” Finasteride effectively reduces symptoms of enlarged prostate with minimal side effects.
25 citations
,
December 2008 in “The Journal of Urology” Short-term finasteride treatment may lower some cell death factors in prostate cancer cells.
Androgen-modulating drugs do not significantly change the heat sensitivity of prostate cancer cells.
9 citations
,
November 2021 in “Infectious Agents and Cancer” Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.
13 citations
,
May 2018 in “Urologic Oncology: Seminars and Original Investigations” Finasteride does not prevent bladder cancer.
March 2013 in “European Urology Supplements”
20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
1 citations
,
November 2002 in “Endocrine practice” The patient's high testosterone was reduced by a medication that suppresses gonadotropin.
August 2003 in “Oncology Times” The trial on testosterone replacement therapy in older men faced concerns due to prostate cancer risk.
May 2021 in “The FASEB Journal” The research gives new understanding on how human steroid 5α-reductases work and how drugs like finasteride inhibit them, which could help in creating new drugs.
73 citations
,
January 1994 in “European Urology” Finasteride works better than Permixon in reducing dihydrotestosterone levels.
Finasteride may help prevent prostate cancer, but more research is needed.
2 citations
,
January 2011 in “Springer eBooks” Finasteride is a medicine used to treat enlarged prostate and prostate cancer, and it works by changing how testosterone works in the body.
April 2016 in “The FASEB Journal” Blocking androgen receptors early in life increases estrogen levels and reduces sexual motivation in male rats.
October 1995 in “Journal of The European Academy of Dermatology and Venereology” August 2023 in “Journal of Investigative Dermatology”
89 citations
,
December 2006 in “Lancet Oncology” Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.
December 2010 in “Asian Journal of Research in Chemistry” The new method makes finasteride cheaper and easier to produce.
27 citations
,
January 1984 in “Pharmacology & Therapeutics” Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.
11 citations
,
June 2016 in “European Journal of Medicinal Chemistry” Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.
December 2013 in “Urology reports (St - Petersburg)” Sonirid Duo effectively treats benign prostatic hyperplasia.
21 citations
,
March 2018 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may help stabilize or slow down hair loss in some frontal fibrosing alopecia patients, but more research is needed to confirm their effectiveness and safety.
237 citations
,
December 2001 in “Urology” Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
6 citations
,
December 2019 in “Dermatologic Therapy” Oral dutasteride improves hair growth, reduces hair loss, and is safe for most patients.
2 citations
,
August 2016 in “British Journal of Clinical Pharmacology” The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.